Radius Health Inc (NASDAQ:RDUS) rose 15.3% during trading on Friday . The stock traded as high as $32.33 and last traded at $31.60. Approximately 3,177,575 shares were traded during trading, an increase of 226% from the average daily volume of 974,337 shares. The stock had previously closed at $27.41.

RDUS has been the topic of several recent analyst reports. Zacks Investment Research cut Radius Health from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Goldman Sachs Group reissued a “neutral” rating and set a $45.00 target price on shares of Radius Health in a report on Friday, October 6th. Maxim Group reissued a “positive” rating on shares of Radius Health in a report on Friday, September 29th. They noted that the move was a valuation call. Jefferies Group dropped their target price on Radius Health from $38.00 to $31.00 and set a “hold” rating on the stock in a report on Friday, November 3rd. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $58.00 target price on shares of Radius Health in a report on Friday, November 3rd. Three analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $48.00.

The company has a debt-to-equity ratio of 0.53, a current ratio of 12.87 and a quick ratio of 12.79.

Radius Health (NASDAQ:RDUS) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03). The business had revenue of $13.50 million for the quarter, compared to analysts’ expectations of $6.90 million. During the same quarter last year, the business posted ($1.07) EPS. research analysts expect that Radius Health Inc will post -5.57 EPS for the current year.

In other news, major shareholder Growth N. V. Biotech acquired 50,000 shares of the stock in a transaction on Tuesday, November 14th. The shares were purchased at an average cost of $26.25 per share, for a total transaction of $1,312,500.00. Following the transaction, the insider now owns 5,698,799 shares in the company, valued at approximately $149,593,473.75. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Growth N. V. Biotech acquired 150,000 shares of the stock in a transaction on Thursday, September 14th. The shares were purchased at an average price of $33.45 per share, for a total transaction of $5,017,500.00. Following the completion of the transaction, the insider now owns 5,448,799 shares in the company, valued at approximately $182,262,326.55. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 367,678 shares of company stock worth $11,746,498. 15.00% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of RDUS. Cubist Systematic Strategies LLC purchased a new position in Radius Health during the 3rd quarter worth approximately $110,000. Sei Investments Co. boosted its stake in shares of Radius Health by 27.7% during the 2nd quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 690 shares during the period. Ameritas Investment Partners Inc. boosted its stake in shares of Radius Health by 19.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 541 shares during the period. Advisor Group Inc. boosted its stake in shares of Radius Health by 267.2% during the 2nd quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 2,888 shares during the period. Finally, Blair William & Co. IL acquired a new stake in shares of Radius Health during the 2nd quarter valued at $205,000.

ILLEGAL ACTIVITY NOTICE: “Radius Health (RDUS) Stock Price Up 15.3%” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/radius-health-rdus-stock-price-up-15-3/1755466.html.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Receive News & Ratings for Radius Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.